Heron Therapeutics Inc. Stock
Price
Target price
€2.95
€2.95
2.230%
0.066
2.230%
€4.59
17.05.24 / Tradegate
WKN: A1XB6K / Symbol: HRTX / Name: Heron Inc / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Heron Therapeutics Inc. Stock
There is an upward development for Heron Therapeutics Inc. compared to yesterday, with an increase of €0.066 (2.230%).
With 11 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
As a result the target price of 4 € shows a positive potential of 35.69% compared to the current price of 2.95 € for Heron Therapeutics Inc..
For the coming years our community has positive and negative things to say abot the Heron Therapeutics Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.
Pros and Cons of Heron Therapeutics Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
B****
?
S********** s********
Cons
?
M***** P*******
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Heron Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Heron Therapeutics Inc. | 2.230% | 14.441% | 6.657% | 154.138% | 87.771% | -73.537% | - |
| Ardelyx Inc. | 0.340% | -0.416% | 16.992% | 98.564% | 24.360% | 28.357% | - |
| Evolus Inc | 5.130% | 4.237% | 11.818% | 41.379% | 35.912% | 70.833% | - |
| Salarius Pharmaceuticals Inc. | 7.850% | -5.069% | -4.630% | -67.040% | -25.766% | -98.502% | -99.992% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-17
Heron Inc (HRTX) seems to be going through significant financial challenges. A closer inspection of the financial statements of the company shows declining assets, increasing liabilities, and persistent negative net income over the past few years. Despite being a part of the promising Biotechnology & Medical Research industry, Heron Inc's financial performance raises concerns about the company's growth and stability.
*Pros: *
Gross Profit Margin Improvement: Heron Inc has managed to improve its gross profit margin from approximately 42% in 2020 to around 49% in 2022. This suggests that it has been successful in controlling its cost of revenues and might be able to continue doing so in the future.
Comments
Heron Therapeutics, Inc. (NASDAQ: HRTX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $5.00 price target on the stock.
Show more
Ratings data for HRTX provided by MarketBeat
Heron Therapeutics, Inc. (NASDAQ: HRTX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $5.00 price target on the stock.
Show more
Ratings data for HRTX provided by MarketBeat
Heron Therapeutics, Inc. (NASDAQ: HRTX) is now covered by analysts at Capital One Financial Co.. They set an "overweight" rating and a $6.00 price target on the stock.
Show more
Ratings data for HRTX provided by MarketBeat
